CD274 and non-small cell lung carcinoma: A retrospective study of 349 NSCLC patients with PD‐L1 tumor proportion score (TPS) ≥ 50% who received immune checkpoint inhibitor‐based first‐line therapy found that higher DpR was associated with longer PFS and OS.